Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke | Cardiology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Adams HP Jr, del Zoppo G, Alberts MJ,  et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups.  Guidelines for the early management of adults with ischemic stroke.  Stroke. 2007;38(5):1655-171117431204PubMedGoogle ScholarCrossref
2.
Wardlaw JM, Murray V, Berge E,  et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke.  Lancet. 2012;379(9834):2364-237222632907PubMedGoogle ScholarCrossref
3.
Meng X, Fisher M, Shen Q, Sotak CH, Duong TQ. Characterizing the diffusion/perfusion mismatch in experimental focal cerebral ischemia.  Ann Neurol. 2004;55(2):207-21214755724PubMedGoogle ScholarCrossref
4.
Saver JL. Time is brain—quantified.  Stroke. 2006;37(1):263-26616339467PubMedGoogle ScholarCrossref
5.
Lees KR, Bluhmki E, von Kummer R,  et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group.  Time to treatment with intravenous alteplase and outcome in stroke.  Lancet. 2010;375(9727):1695-170320472172PubMedGoogle ScholarCrossref
6.
Saver JL, Levine SR. Alteplase for ischaemic stroke—much sooner is much better.  Lancet. 2010;375(9727):1667-166820472152PubMedGoogle ScholarCrossref
7.
Strbian D, Soinne L, Sairanen T,  et al; Helsinki Stroke Thrombolysis Registry Group.  Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality.  Stroke. 2010;41(4):712-71620167917PubMedGoogle ScholarCrossref
8.
Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke.  Neurology. 2005;65(8):1169-117416247041PubMedGoogle ScholarCrossref
9.
Sobesky J, Frackowiak M, Zaro Weber O,  et al.  The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis.  Cerebrovasc Dis. 2007;24(1):56-6517519545PubMedGoogle ScholarCrossref
10.
LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the “Get With The Guidelines” program.  Arch Intern Med. 2008;168(4):411-41718299497PubMedGoogle ScholarCrossref
11.
Schwamm LH, Fonarow GC, Reeves MJ,  et al.  Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack.  Circulation. 2009;119(1):107-11519075103PubMedGoogle ScholarCrossref
12.
Saver JL, Gornbein J, Grotta J,  et al.  Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window.  Stroke. 2009;40(7):2433-243719498197PubMedGoogle ScholarCrossref
13.
Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale.  Stroke. 2009;40(6):2079-208419372447PubMedGoogle ScholarCrossref
14.
Mazya M, Egido JA, Ford GA,  et al.  Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase.  Stroke. 2012;43(6):1524-153122442178PubMedGoogle ScholarCrossref
15.
Fonarow GC, Smith EE, Saver JL,  et al.  Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke.  Circulation. 2011;123(7):750-75821311083PubMedGoogle ScholarCrossref
16.
Fonarow GC, Saver JL, Smith EE,  et al.  Relationship of National Institutes of Health Stroke Scale to 30-day mortality in Medicare beneficiaries with acute ischemic stroke.  J Am Heart Assoc. 2012;1(1):42-5023130117PubMedGoogle ScholarCrossref
17.
Hodgson C, Lindsay P, Rubini F. Can mass media influence emergency department visits for stroke?  Stroke. 2007;38(7):2115-212217540967PubMedGoogle ScholarCrossref
18.
Robinson TG, Reid A, Haunton VJ, Wilson A, Naylor AR. The face arm speech test: does it encourage rapid recognition of important stroke warning symptoms [published online ahead of print July 4, 2012]?  Emerg Med J. 2012;30(6):467-47122764171PubMedGoogle ScholarCrossref
19.
Morgenstern LB, Gonzales NR, Maddox KE,  et al.  A randomized, controlled trial to teach middle school children to recognize stroke and call 911.  Stroke. 2007;38(11):2972-2978Google ScholarCrossref
20.
Boden-Albala B, Stillman J, Perez T,  et al.  A stroke preparedness RCT in a multi-ethnic cohort.  Contemp Clin Trials. 2010;31(3):235-24120193777PubMedGoogle ScholarCrossref
21.
Acker JE III, Pancioli AM, Crocco TJ,  et al.  Implementation strategies for emergency medical services within stroke systems of care.  Stroke. 2007;38(11):3097-311517901393PubMedGoogle ScholarCrossref
22.
Schwamm LH, Pancioli A, Acker JE III,  et al; American Stroke Association's Task Force on the Development of Stroke Systems.  Recommendations for the establishment of stroke systems of care.  Stroke. 2005;36(3):690-70315689577PubMedGoogle ScholarCrossref
23.
Lin CB, Peterson ED, Smith EE,  et al.  Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke.  Circ Cardiovasc Qual Outcomes. 2012;5(4):514-52222787065PubMedGoogle ScholarCrossref
24.
 A systems approach to immediate evaluation and management of hyperacute stroke.  Stroke. 1997;28(8):1530-15409259745PubMedGoogle ScholarCrossref
25.
Tveiten A, Mygland A, Ljøstad U, Thomassen L. Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre.  Emerg Med J. 2009;26(5):324-32619386862PubMedGoogle ScholarCrossref
26.
Köhrmann M, Schellinger PD, Breuer L,  et al.  Avoiding in hospital delays and eliminating the three-hour effect in thrombolysis for stroke.  Int J Stroke. 2011;6(6):493-49721609415PubMedGoogle ScholarCrossref
27.
Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis.  Neurology. 2012;79(4):306-31322622858PubMedGoogle ScholarCrossref
28.
Xian Y, Fonarow GC, Reeves MJ,  et al.  Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke).  Am Heart J. 2012;163(3):392-39822424009PubMedGoogle ScholarCrossref
29.
Reeves MJ, Fonarow GC, Smith EE,  et al.  Representativeness of the Get With The Guidelines–Stroke Registry: comparison of patient and hospital characteristics among Medicare beneficiaries hospitalized with ischemic stroke.  Stroke. 2012;43(1):44-4921980197PubMedGoogle ScholarCrossref
30.
Ovbiagele B, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level.  Cerebrovasc Dis. 2010;29(1):50-5619893312PubMedGoogle ScholarCrossref
31.
Zhang Q, Saver JL. The relation between destination on hospital discharge and final 3 month disability outcome in acute ischemic stroke. Stroke. 2013;44:ATP379. http://stroke.ahajournals.org/cgi/content/meeting_abstract/44/2_MeetingAbstracts/ATP379. Accessed May 31, 2013
Original Contribution
June 19, 2013

Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke

Author Affiliations

Author Affiliations: Department of Neurology (Dr Saver), and Division of Cardiology (Dr Fonarow), David Geffen School of Medicine at UCLA, Los Angeles, California; Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (Dr Smith); Department of Epidemiology, Michigan State University, East Lansing (Dr Reeves); Duke Clinical Research Center, Durham, North Carolina (Drs Grau-Sepulveda, Pan, Olson, Hernandez, and Peterson); and Department of Neurology, Massachusetts General Hospital, Boston (Dr Schwamm). Dr Olson is now with the Department of Neurology and Neurotherapeutics, University of Texas Southwestern, Dallas.

JAMA. 2013;309(23):2480-2488. doi:10.1001/jama.2013.6959
Abstract

Importance Randomized clinical trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent. However, modest sample sizes have limited characterization of the extent to which onset to treatment (OTT) time influences outcome; and the generalizability of findings to clinical practice is uncertain.

Objective To evaluate the degree to which OTT time is associated with outcome among patients with acute ischemic stroke treated with intraveneous tPA.

Design, Setting, and Patients Data were analyzed from 58 353 patients with acute ischemic stroke treated with tPA within 4.5 hours of symptom onset in 1395 hospitals participating in the Get With The Guidelines-Stroke Program, April 2003 to March 2012.

Main Outcomes and Measures Relationship between OTT time and in-hospital mortality, symptomatic intracranial hemorrhage, ambulatory status at discharge, and discharge destination.

Results Among the 58 353 tPA-treated patients, median age was 72 years, 50.3% were women, median OTT time was 144 minutes (interquartile range, 115-170), 9.3% (5404) had OTT time of 0 to 90 minutes, 77.2% (45 029) had OTT time of 91 to 180 minutes, and 13.6% (7920) had OTT time of 181 to 270 minutes. Median pretreatment National Institutes of Health Stroke Scale documented in 87.7% of patients was 11 (interquartile range, 6-17). Patient factors most strongly associated with shorter OTT included greater stroke severity (odds ratio [OR], 2.8; 95% CI, 2.5-3.1 per 5-point increase), arrival by ambulance (OR, 5.9; 95% CI, 4.5-7.3), and arrival during regular hours (OR, 4.6; 95% CI, 3.8-5.4). Overall, there were 5142 (8.8%) in-hospital deaths, 2873 (4.9%) patients had intracranial hemorrhage, 19 491 (33.4%) patients achieved independent ambulation at hospital discharge, and 22 541 (38.6%) patients were discharged to home. Faster OTT, in 15-minute increments, was associated with reduced in-hospital mortality (OR, 0.96; 95% CI, 0.95-0.98; P < .001), reduced symptomatic intracranial hemorrhage (OR, 0.96; 95% CI, 0.95-0.98; P < .001), increased achievement of independent ambulation at discharge (OR, 1.04; 95% CI, 1.03-1.05; P < .001), and increased discharge to home (OR, 1.03; 95% CI, 1.02-1.04; P < .001).

Conclusions and Relevance In a registry representing US clinical practice, earlier thrombolytic treatment was associated with reduced mortality and symptomatic intracranial hemorrhage, and higher rates of independent ambulation at discharge and discharge to home following acute ischemic stroke. These findings support intensive efforts to accelerate hospital presentation and thrombolytic treatment in patients with stroke.

×